ASAQ Winthrop®

Sanofi

Product category
  • Artemisinin-based Combination Therapy (ACT)

  • Artesunate-amodiaquine

Therapeutic indication
  • Treatment of uncomplicated P. falciparum malaria in adults, children and infants >5kg
Dosing
  • Once-daily for 3 days

Efficacy
  • 28 day PCR-corrected ACPR* 94.4%–98.9%

Key features
  • Low price compared to other prequalified ACTs (public-sector tenders)

  • Three-year shelf life

Challenges
  • Amodiaquine resistance in some countries

  • Being withdrawn from countries where SPAQ is deployed for seasonal malaria chemoprevention (SMC) following WHO recommendation

Status
  • 537 million treatments distributed since 2007

  • Approved in 33 countries (see map)

Previously
  • DNDi and partners completed development and registration. Incorporated into MMV portfolio via collaboration supporting phase IV safety study in Côte d’Ivoire in 2010

MMV Project Director
  • Adam Aspinall

* ACPR = adequate clinical and parasitological response